Research from Mimio Health, a California-based company, reveals a promising formulation known as Mimio, designed to replicate the health benefits associated with fasting. Fasting has been shown to enhance healthspan and lifespan in various model organisms, making this development particularly noteworthy.
A study published in Scientific Reports demonstrated that after eight weeks of supplementation with Mimio, significant improvements were noted in total cholesterol, LDL cholesterol, oxidized LDL, and fasting glucose levels when compared to a placebo group.
“These findings illustrate, in a rigorously controlled placebo trial, that Mimio’s fasting mimetic formulation can offer similar metabolic, cellular, and appetite-regulating benefits as traditional fasting—without the need to fast,” said Dr. Chris Rhodes, PhD, CEO of Mimio Health and a corresponding author of the study.
“We observed noticeable improvements in cholesterol and glucose metabolism, oxidative stress, digestion, and hunger control that are reminiscent of earlier results seen with a 36-hour fast, all without requiring participants to alter their eating habits or lifestyle.”
At-Home Results
The study was conducted by People Science, a pioneering organization that specializes in decentralized clinical trials. With its advanced platform, Chloe, they aim for rapid, scalable, and scientifically robust research.
Azure Grant, PhD, head of research at People Science and lead author of the study, noted, “People are constantly trying new health solutions; the vital task is to harness that data for scientific exploration.”
“Our collaboration with Mimio showcases the potential of conducting research from the comfort of one’s home,” she explained. “Together with our participants, Mimio, and People Science, we set out to determine if the advantages of fasting can be achieved without skipping meals. By simply ingesting the molecules produced by the body during fasting, we observed improvements in hunger, satiety, and even various cardiometabolic indicators.”
“Our digital tool, Chloe, supported an impressive 94% adherence rate, generated personalized insights, and provided high-quality data leading to a publication in Scientific Reports.
Study Overview
Drs. Rhodes and Grant, along with their team, enlisted 42 older adults (average age 62) with elevated BMI and HbA1c levels for their randomized, double-blind, placebo-controlled clinical trial. Participants were assigned to either receive a placebo or the Mimio fasting mimetic daily, 30 to 60 minutes before their first meal.
The formulation of Mimio includes 250 mg of nicotinamide, 600 mg of PEA (Palmitoylethanolamide), 400 mg of OEA (Oleoylethanolamide), and 8 mg of spermidine.
Subjective feedback collected over the eight weeks indicated that individuals in the Mimio group exhibited greater improvements in hunger and satiety metrics compared to those in the placebo group. Remarkably, 91% of participants using Mimio reported enhanced meal-time appetite regulation, contrasting with only 47% in the placebo group.
Additionally, participants in the Mimio group reported significantly less abdominal discomfort and bloating than those receiving the placebo.
Comprehensive metabolic bloodwork conducted at both the beginning and end of the study revealed that the Mimio group experienced “fasting-like benefits concerning cardiometabolic blood markers,” as highlighted by the researchers. Improvements included significant reductions in LDL particle numbers, total cholesterol, oxidized LDL, as well as LDL, non-HDL, and glucose concentrations.
“This research exemplifies our ability to investigate complex biological mechanisms under real-world conditions while adhering to strict scientific standards,” stated Noah Craft, MD, PhD, co-CEO of People Science, in a press release. “By combining a decentralized framework with biomarker-based endpoints, we’re able to accelerate the transition from hypothesis to evidence, ultimately guiding future scientific inquiries.”
The researchers believe that subsequent longer-term studies involving larger populations may demonstrate that Mimio can assist with weight loss and potentially establish a new homeostatic setpoint for lipid metabolism.
“Given the lifespan-extending properties of Mimio and its key ingredients found in previous research, future investigations should explore its potential to reduce markers of biological aging in human populations, particularly among older adults for whom fasting might pose health risks,” they concluded.
Source: Science Reports, 2026, 16, 7812. doi: 10.1038/s41598-026-38495-7. “A novel fasting mimetic (Mimio) creates fasting-like benefits to hunger control, oxidative stress, and cardiometabolic health in humans”. Authors: A.D. Grant, et al.
